Administration of antiretroviral post-exposure prophylaxis (PEP) to decrease HIV infection in individuals exposed to HIV

  • Protocol
  • Intervention


  • J Laurie,

  • G Kennedy,

    Review Group Coordinator, Corresponding author
    1. AIDS Research Institute, Cochrane CRG on HIV Infection and AIDS, San Francisco, California, USA
    • G Kennedy, Review Group Coordinator, Cochrane CRG on HIV Infection and AIDS, AIDS Research Institute, 74 New Montgomery Street, Suite 600, San Francisco, California, 94105, USA.

    Search for more papers by this author
  • G Rutherford


This is the protocol for a review and there is no abstract. The objectives are as follows:

1. To locate and describe available outcome studies evaluating the efficacy of PEP regimes (i.e. the prevention of seroconversion) and the efficacy of PEP when applied to different modes of HIV exposure in the populations described previously. To do this we shall look at PEP compared to placebo, one PEP regimen compared to another and the efficacy of immediately given PEP compared to delayed PEP. We shall also examine the frequency of side effects, issues of cost effectiveness and non-adherence.

2. To undertake a critical review of the quality of these studies, addressing factors determining internal and external validity, including study design, implementation and loss to follow up.

3. To conduct empirical synthesis, including meta-analysis if warranted, to address our questions about PEP and its uses.

4. To summarize the current protocols for PEP and the evidence associated with them among our identified populations.

5 Highlight future research, policy, and practice needs.